20‐year follow‐up of Hodgkin lymphoma: Predictors of survival and secondary malignancies

Abstract

Introduction: The prognosis of Hodgkin lymphoma (HL) has improved significantly with the implementation of a risk‐adapted treatment that combines chemo and radiotherapy. Nevertheless, the benefit in terms of overall survival (OS) has been jeopardized by long‐term toxicity. The identification of risk factors is crucial to assign each patient to a well‐ defined risk group and prevent undertreatment or overtreatment, minimizing the risk of relapse and long‐term toxicity.